Kosin Medical Journal

Review articles

Gut microbiota and nonalcoholic fatty liver disease: Boyeon Kim, Bukyung Kim; Kosin Med J. 2023;38(3):169-175. Published online September 22, 2023; DOI: https://doi.org/10.7180/kmj.23.138

3,783 View
78 Download
1 Citations

The gut microbiota has been reported to exert a significant influence on various physiological responses of hosts. Extensive evidence has recently emerged linking metabolic and cardiovascular disorders to the gut microbiota. Nonalcoholic fatty liver disease (NAFLD) is the most common underlying metabolic disorder, and its prevalence is increasing worldwide. In this study, we aim to review the relationship between the gut microbiota and NAFLD, and explore the potential of the gut microbiota as a novel target for NAFLD treatment.

Citations

Citations to this article as recorded by

Beneficial Effects of the Ketogenic Diet on Nonalcoholic Fatty Liver Disease (NAFLD/MAFLD)
Damian Dyńka, Łukasz Rodzeń, Mateusz Rodzeń, Dorota Łojko, Sebastian Kraszewski, Ali Ibrahim, Maria Hussey, Adam Deptuła, Żaneta Grzywacz, Alexandre Ternianov, David Unwin
Journal of Clinical Medicine.2024; 13(16): 4857. CrossRef

Revolutionizing gut health: exploring the role of gut microbiota and the potential of microbiome-based therapies in lower gastrointestinal diseases: Yong Eun Park, Jae Hyun Kim; Kosin Med J. 2023;38(2):98-106. Published online June 23, 2023; DOI: https://doi.org/10.7180/kmj.23.115

3,594 View
71 Download
2 Citations

Abstract PDF PubReader ePub

The gut microbiota comprises a collection of microorganisms residing in the human digestive system, including bacteria, viruses, and fungi. These microbes have critical roles in food breakdown, immune system regulation, and the production of essential nutrients. Several lower gastrointestinal (GI) diseases, including inflammatory bowel disease, irritable bowel syndrome, and colorectal cancer, have been associated with dysbiosis, which refers to an imbalance in the gut microbiota. Additionally, the gut microbiome and its microbial compounds affect disease development and the host’s immune response. Alterations in the gut-brain axis microbiome are also implicated in lower GI diseases. Therefore, microbiome-based therapies that regulate the gut microbiota (e.g., fecal microbiota transplantation and probiotics) are essential for the prevention and treatment of these diseases. This review aims to highlight the significance of gut microbiota and microbiome-based therapies in managing lower GI diseases.

Citations

Citations to this article as recorded by

Advances in research on the intestinal microbiota in the mechanism and prevention of colorectal cancer (Review)
Weitong Sun, Shize Ma, Dongdong Meng, Chaoxing Wang, Jinbo Zhang
Molecular Medicine Reports.2025; 31(5): 1. CrossRef
From Food Supplements to Functional Foods: Emerging Perspectives on Post-Exercise Recovery Nutrition
Lifeng Wang, Qing Meng, Chun-Hsien Su
Nutrients.2024; 16(23): 4081. CrossRef

First
Prev
Page of 1
Next
Last

Search